Fig. 3From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in SwitzerlandIncremental cost-effectiveness plane for the probabilistic sensitivity analysis. CHF, Swiss francs; QALYs, quality-adjusted life years; SoC, standard of care; VN, voretigene neparovecBack to article page